Board members: Anne-Marie Duliege
Anne-Marie Duliege, M.D.
An executive officer of a Commercial Life Science Entity
Appointed by the Controller
Dr. Duliege has over 20 years of scientific and leadership experience in the pharmaceutical industry. She joined Affymax in 2004 as VP of clinical, regulatory and medical affairs. She was instrumental in raising capital and taking the company public. She was promoted to Chief Medical Officer in 2007. Under her leadership, her team completed an extensive development program and obtained FDA’s approval for the company’s lead product, OMONTYS®. As a member of the executive team, Dr. Duliege is responsible for the clinical and non-clinical research of the company and helps set company strategies, contributes to investor relations, and supports business development activities.
Prior to joining Affymax, Dr. Duliege was a Senior Medical Director at Chiron Corporation with a record of significant accomplishments in executing Phase 1 through 4 clinical studies in pulmonary medicine, infectious disease and immunology. She held positions of Senior Research Physician at Genentech, Inc., working on HIV treatment and vaccine, and epidemiologist at the National Institute of Science & Medical Research in Paris.
Dr. Duliege received her MD degree and her certification in Pediatrics from Paris Medical School; she also has an M.S. in Epidemiology from Harvard School of Public Health and an M.S. in Biostatistics from Paris Medical School. She continues to practice medicine as an Adjunct Clinical Assistant Professor at Stanford’s School of Medicine and Lucile Packard Children’s Hospital. She serves on the board of non-profit organizations focused on the prevention of HIV. She is personally committed to supporting public health efforts in developing countries.